
Nabla Bio is a Cambridge, MA-based company pioneering AI-powered protein design to expand the universe of druggable targets. Founded by experts in protein language modeling, Nabla integrates generative AI models with massively multiplexed experimental technologies to design antibodies with atomic precision, targeting challenging disease proteins such as GPCRs and ion channels. Their platform combines AI-guided drug design with empirical wet-lab measurements to optimize manufacturability, safety, and efficacy of novel therapeutics. Nabla partners with leading pharmaceutical companies including AstraZeneca, Bristol Myers Squibb, and Takeda to accelerate drug discovery and development. The company operates a fully in-person, highly technical team focused on advancing drug design through innovative AI and experimental methods, positioning itself as a cutting-edge player in the biopharmaceutical AI space.

Nabla Bio is a Cambridge, MA-based company pioneering AI-powered protein design to expand the universe of druggable targets. Founded by experts in protein language modeling, Nabla integrates generative AI models with massively multiplexed experimental technologies to design antibodies with atomic precision, targeting challenging disease proteins such as GPCRs and ion channels. Their platform combines AI-guided drug design with empirical wet-lab measurements to optimize manufacturability, safety, and efficacy of novel therapeutics. Nabla partners with leading pharmaceutical companies including AstraZeneca, Bristol Myers Squibb, and Takeda to accelerate drug discovery and development. The company operates a fully in-person, highly technical team focused on advancing drug design through innovative AI and experimental methods, positioning itself as a cutting-edge player in the biopharmaceutical AI space.
Headquarters: Cambridge, Massachusetts
Founded: 2020
Core product: AI-driven de novo antibody and protein design platform
Employees (approx.): 22
Notable investors: Khosla Ventures, Zetta Venture Partners, Radical Ventures
| Company |
|---|
Drug discovery / therapeutic protein and antibody design
2020
Biotechnology
11000000
Reported $11M priced seed round with participation from Fifty Years and Cantos Ventures.
Series A announced May 14, 2024; participation reported from Zetta Venture Partners, Y Combinator, Khosla Ventures, Fifty Years, Cantos, Boom Capital Ventures.
“Boom Capital Ventures, Cantos, Fifty Years, Khosla Ventures, Pillar VC, Radical Ventures, Y Combinator, Zetta Venture Partners”